NCT05201066 2026-01-07Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.NovartisPhase 2 Active not recruiting33 enrolled
NCT03066648 2025-05-18Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSNovartisPhase 1 Completed241 enrolled